Combining ThioLogics’ site-specific conjugation chemistry with Albumedix’s drug delivery platform for the creation of next-generation albumin drug conjugates.
London, UK and Copenhagen, Denmark – Albumedix announced new data that supports an exclusive agreement with ThioLogics, a UCL Business (UCLB) company, to commercialize the next generation of stable albumin drug conjugates.
The data demonstrates the serum stability advantages achieved by combining Albumedix’s albumin-based drug delivery technology, Veltis®, with ThioLogics’ site-specific Next Generation Maleimide (NGM) chemistry platform, allowing significant improvements in cost of goods compared to conventional maleimide conjugation approaches.
Albumedix’s agreement with ThioLogics unites its modified recombinant human albumin Veltis technology, with ThioLogics’ site-specific NGM chemistry platform, to create serum stable albumin drug conjugates with enhanced pharmacokinetic and delivery capabilities. The new data indicates that the linking of the two platforms improves stability profiles in vivo for both natural and synthesized peptides and small molecules, with the potential for an enhanced safety profile and, therefore, increased patient compliance for drug products. Additionally, the data reveals that no losses are observed during controlled hydrolysis when using the technology to produce albumin drug conjugates in vitro (Org. Biomol. Chem., 2015, 13, 7946-7949).
“Combining the benefits of Albumedix’s and ThioLogics’ technology platforms through this commercialization agreement allows us to jointly offer customers new capabilities to design stable and efficacious products across a broad-spectrum of drug candidates,” said Dr Dave Mead, Business Development Director at Albumedix. “With an exclusive licensing agreement now in place, we look forward to working with our customers to show what can be achieved through this novel technology to link drugs to albumin.”
“We are delighted to have formalized our exclusive marketing agreement with Albumedix, and to be making the promises of this combined technology platform a reality for our customers,” commented Dr Chris Williams, Senior Business Manager at UCLB. “Together we have made it possible for manufacturers to harness the advantages of serum stable drug conjugates with tailored pharmacokinetics, helping to maximize the potential of novel drugs.”
“Securing the Albumedix agreement is a major validation of Thiologics’ novel technology which has the potential to revolutionize the assembly of next generation biologics”, said Cengiz Tarhan, Managing Director of UCLB.